Violation Tracker Individual Record

Company: 
Schering-Plough Corporation
Current Parent Company: 
Merck
Penalty: 
$435,000,000
Primary Offense: 
off-label or unapproved promotion of medical products
Secondary Offense: 
fraud
Violation Description: 

Schering-Plough agreed to pay $435 million to resolve criminal charges and civil liabilities in connection with illegal sales and marketing programs for its drugs Temodar (used in the treatment of brain tumors and metastases) and Intron A (used in treatment of superficial bladder cancer and hepatitis C). The resolution also pertained to Medicaid fraud involving Schering's drugs Claritin RediTabs, a non-sedating antihistamine, and K-Dur, used in treating stomach conditions.

Year: 
2006
Date: 
August 29, 2006
Agency: 
U.S. Attorney-District of Massachusetts
Civil or Criminal Case: 
civil and criminal
HQ Country of Parent: 
USA
HQ State of Parent: 
New Jersey
Ownership Structure of Parent: 
publicly traded
Major Industry of Parent: 
pharmaceuticals
Specific Industry of Parent: 
pharmaceuticals
Source Notes: 
If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Parent company note: 
Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.